News
-
Social Media Valuable Tool For Recruiting Study Participants
9/6/2011
Mayo Clinic has identified a new benefit of social media and online networking: a novel way to study rare diseases. Through patient-run websites dedicated to heart conditions and women's heart health, a team of cardiologists led by Sharonne Hayes, M.D., is reaching out to survivors of spontaneous coronary artery dissection, also known as SCAD, a poorly understood heart condition that affects just a few thousand Americans every year.
-
Ultrasensitive Particles Offer New Way To Find Cancer
9/2/2011
About 10 years ago, scientists discovered a new type of genetic material called microRNA, which appears to turn genes on or off inside a cell. More recently, they found that these genetic snippets often go haywire in cancer cells, contributing to tumors’ uncontrollable growth.
-
Afexa Announces Results Of A Clinical Trial Of Dilexaponan™ For Cholesterol Management
8/23/2011
Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX® - today announced promising results of a pilot clinical study investigating the effects of a new formulation, Dilexaponan™ (LIP-01) on cholesterol management.
-
XOMA Reports Second Quarter 2011 Financial Results
8/8/2011
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced its financial results for the second quarter and six months ended June 30, 2011 and provided a general business update.
-
Aastrom Announces Agreement From FDA On Special Protocol Assessment For Phase 3 Clinical Trial In No-Option Critical Limb Ischemia Patients
8/1/2011
Aastrom Biosciences, Inc. , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the Special Protocol Assessment (SPA) for the design of the Phase 3 REVIVE-CLI clinical trial of ixmyelocel-T, the company's expanded multicellular therapy, in patients with critical limb ischemia (CLI) who have no other treatment options.
-
AtCor Medical Expands Clinical Trials BP Core Lab Offering By Adding SunTech Medical's Ambulatory Blood Pressure
8/1/2011
AtCor Medical the developer and marketer of the SphygmoCor® system, which measures central blood pressures and arterial stiffness noninvasively, and SunTech Medical Inc., a leader in noninvasive blood pressure products and technologies, today announced that they have entered into an exclusive, multi-year worldwide clinical trials distribution and data management agreement.
-
Edwards Lifesciences' Advanced Critical Care Platform Now Available In The U.S
7/25/2011
Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, recently announced that the U.S. Food and Drug Administration (FDA) has given 510(k) clearance for its new EV1000 clinical monitoring platform.
-
Cardiology Researcher Dr. Wojciech Zareba Addresses Need To Improve Risk Stratification Of Heart Failure Patients Eligible For ICD Or CRT-D
6/29/2011
Responding to a recent study showing that 40% of patients who receive CRT-ICD therapy do not benefit from the device (Sipahi, et al – 6/13/11), Wojciech Zareba, MD, PhD, stated that improving risk stratification of heart failure patients eligible for an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D) is essential.
-
NIH Stops Clinical Trial On Combination Cholesterol Treatment
5/27/2011
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned.
This website uses cookies to ensure you get the best experience on our website. Learn more